| Literature DB >> 29944672 |
Barbara Wróblewska1, Anna Maria Szyc1, Lidia Hanna Markiewicz1, Magdalena Zakrzewska2, Ewa Romaszko3.
Abstract
INTRODUCTION: The study evaluates the impact of biopsychosocial factors involved in food allergy (FA) on the prevalence of eating disorders (ED). For the 5-year follow-up studies, 75 participants (aged 1-14 years) with early-onset FA and 81 healthy peers were included.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29944672 PMCID: PMC6019672 DOI: 10.1371/journal.pone.0198607
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Demographic and descriptive parameters of subjects during the recruitment and the 5-year follow-up phases of the study, according to health status categories.
| • Groups by health status categories | Recruitment phase of the study | 5 year follow up studies | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| FA- | Type of food allergy (FA+) | Control Group (FA-) | Type of food allergy (FA+) | ||||||||
| FA+S | FA+P | FA+M | FA+S | FA+P | FA+M | ||||||
| n = 90 (3) | n = 9 | n = 26 | n = 55 | n = 81 | n = 6 | n = 35 | n = 34 | ||||
| 5.5 [3.4] | 5.2 [2.3] | 6.5 [3.9] | 6.4 [3.9] | 0.869 | 11.1 [3.9] | 11.3 [2.0] | 12.7 [4.2] | 10.2 [3.6] | 0.883 | 0.370 | |
| 50 (55.6) | 5 (55.6) | 14 (53.8) | 36 (65.5) | 0.642 | 45 (55.6) | 4 (66.6) | 17 (48.6) | 16 (47.2) | 0.629 | 0.089 | |
| 63 (70) | 7 (77.8) | 19 (73) | 43 (78.2) | 0.738 | 57 (70.4) | 4 (66.6) | 27 (77.1) | 24 (70.6) | 0.902 | 0.160 | |
| 36 (40.0) | 2 (22.2) | 7 (27.0) | 16 (29.1) | 31 (38.3) | 1 (16.6) | 6 (17.1) | 8 (23.5) | ||||
| Infant formulas | 16 (17.8) | 5 (55.6) | 14 (53.8) | 20 (36.4) | 15 (18.5) | 4 (66.6) | 19 (54.3) | 15 (44.1) | 0.321 | ||
| Mixed breastfeeding & formulas | 38 (42.2) | 2 (22.2) | 5 (19.2) | 19 (34.5) | 35 (43.2) | 1 (16.6) | 10 (28.6) | 11 (32.4) | |||
| 63 (70.0) | 9 (100) | 22 (84.6) | 42 (76.4) | 0.133 | 48 (59.3) | 4 (66.6) | 19 (54.3) | 29 (85.3) | 0.041 | ||
| Village | 27 (30.0) | 0 (0.0) | 4 (16.4) | 13 (23.6) | 33 (40.7) | 2 (33.4) | 16 (45.7) | 5 (14.7) | |||
| 25 (27.8) | 5 (55.6) | 20 (76.9) | 12 (18.8) | 20 (24.7) | 4 (66.6) | 17 (48.6) | 12 (35.3) | 0.023 | |||
| 0 (0.0) | 6 (66.7) | 21 (80.8) | 21 (38.2) | 0.014 | 0 (0.0) | 6 (100.0) | 15 (42.9) | 18 (52.9) | 0.790 | ||
| Respiratory manifestation | 0 (0.0) | 2 (22.2) | 1 (3.8) | 10 (18.2) | 0 (0.0) | 0 (0.0) | 9 (25.7) | 9 (26.5) | |||
| Skin/mucosal manifestation | 0 (0.0) | 1 (11.1) | 4 (15.4) | 24 (43.6) | 0 (0.0) | 0 (0.0) | 11 (31.4) | 7 (20.6) | |||
| 0 (0.0) | 7 (77.8) | 10 (38.5) | 25 (45.5) | 0.321 | 0 (0.0) | 4 (66.6) | 10 (28.6) | 18 (52.9) | 0.118 | ||
| Serum tests | 0 (0.0) | 1 (11.1) | 4 (15.4) | 4 (7.3) | 0 (0.0) | 1 (16.6) | 19 (54.3) | 15 (44.1) | |||
| Oral challenge | 0 (0.0) | 1 (11.1) | 2 (7.7) | 2 (3.6) | 0 (0.0) | 1 (16.6) | 6 (17.1) | 1 (2.9) | 0.960 | ||
| 1 (1.1) | 8 (88.9) | 17 (65.4) | 26 (40.6) | 4 (4.9) | 6 (100.0) | 29 (82.9) | 13 (38.2) | ||||
| Antihistamine drugs | 0 (0.0) | 6 (66.7) | 6 (23.1) | 29 (45.3) | 0 (0.0) | 4 (66.6) | 19 (54.3) | 22 (64.7) | |||
| Steroids | 0 (0.0) | 1 (11.1) | 3 (11.5) | 18 (28.1) | 0 (0.0) | 1 (16.6) | 9 (25.7) | 13 (38.2) | 0.159 | ||
| Desensitization | 0 (0.0) | 0 (0.0) | 0 (0.0) | 9 (14.1) | 0 (0.0) | 0 (0.0) | 5 (14.3) | 7 (20.6) | 0.083 | ||
| 15 (16.7) | 1 (9.0) | 4 (15.4) | 14 (25.5) | 0.493 | 15 (18.5) | 3 (50.0) | 17 (48.6) | 15 (44.1) | |||
| 13 (14.4) | 3(33.3) | 8 (30.8) | 19 (34.6) | 9 (11.1) | 3 (50.0) | 16 (45.7) | 13 (38.2) | 0.181 | |||
| Normal | 71 (78.9) | 5 (55.6) | 13 (50.0) | 23 (41.8) | 64 (79.0) | 3 (50.0) | 8 (22.9) | 17 (50.0) | |||
| Overweight | 6 (6.7) | 1 (11.1) | 5 (19.2) | 13 (23.6) | 8 (9.9) | 0 (0.0) | 11 (31.4) | 4 (11.8) | 0.080 | ||
FA-–control group, FA+S–allergy to single food-origin allergen, FA+P–polyallergy to various food-origin allergens, FA+M–mixed polyallergy to aero- and food-origin allergens. ELD–elimination diet. Data are presented as the means [SD] or percentages. Significant associations are marked in bold. Arrows: ↑– significant increase, ↓– significant decrease.
a p value of the Fisher’s exact test for comparison between groups with Bonferroni’s (PB) corrected significance threshold of 0.008.
b p value of the Kruskal-Wallis test for quantitative data for comparison between groups.
c p value of the Q Cochran test for dependent groups in follow-up studies for qualitative data.
d p value of the Friedman test for dependent groups in follow-up studies for quantitative data.
e Classified according to the WHO classification [21, 22].
Prevalence of disordered eating ED+ (stated if both SCOFF and EAT-8 were positive) in groups categorized by age, gender, new-born feeding type, weight status, type of allergy syndromes, diagnostic method and implemented therapy.
| Health status: | FA- | Type of food allergy (FA+) | |||
|---|---|---|---|---|---|
| FA+S | FA+P | FA+M | P-value | ||
| 5.0 (0.2; 7.9) | 10.5 (3.4; 16.6) | 13.8 (6.2; 21.3) | 17.5 (13.6; 21.4) | ||
| Male | 7.9 (1.8; 14.0) | 13.2 (8.3; 17.9) | 18.4 (9.6; 27.2) | 14.5 (6.5; 22.5) | |
| 6.3 (0.7;14.3) | 12.5 (5.9; 20.9) | 18.8 (5.2; 32.2) | 25.0 (6.5; 43.5) | 0.012 | |
| 7–14 | 6.2 (0.9; 11.5) | 3.7 (0.4; 7.8) | 9.9 (3.4; 16.4) | 16.0 (8.2; 24.1) | |
| >15 | 8.5 (1.3; 15.7) | 0.0 (0.0; 0.0) | 17.0 (7.4; 26.7) | 23.6 (4.8; 42.4) | |
| 5.8 (0.7; 12.7) | 2.2 (0.2; 5.3) | 10.1 (3.8; 16.4) | 8.9 (2.9; 14.9) | ||
| Infant formulas | 12.3 (1.4; 26.0) | 8.0 (0.7; 15.4) | 24.2 (6,2; 42.2) | 16.0 (0.5; 31.5) | |
| Mixed breast & formulas | 6.7 (1.5; 11.9) | 5.9 (0.6; 12.4) | 11.8 (2.9; 20.7) | 23.8 (12.0; 35.6) | |
| 12.1 (0.8; 23.4) | 18.2 (4.8; 31.5) | 15.2 (2.7; 27.6) | 31.2 (7.1; 55.4) | 0. 016 | |
| Normal | 4.1 (0.1; 8.1) | 5.2 (0.7; 9.6) | 17.5 (9.9; 25.1) | 13.4 (6.6; 20.2) | |
| Overweight | 11.1 (0.5; 24.7) | 7.4 (0.2; 15.9) | 18.5 (2.8; 34.2) | 14.8 (0.6; 23.8) | |
| 3.7 (0.9; 7,3) | 7.4 (1.2; 15.7) | 25.0 (8.9; 41.1) | 22.2 (5.5; 38.9) | 0.358 | |
| Serum albumin deficiency < 35 g/L | 5.0 (0.8; 8.8) | 10.0 (0,5; 19.5) | 37.0 (17.5; 56.5) | 15.0 (7.2; 22.8) | |
| 0.0 (0.0; 2.4) | 8.1 (2.7; 13.5) | 16.2 (9.2; 23.2) | 18.9 (9.0; 28.9) | ||
| Respiratory manifestation | 0.0 (0.0; 0.0) | 0.0 (0.0; 2.4) | 5.0 (1.5; 8.5) | 11.8 (4.7; 18.9) | |
| Skin/mucosal manifestation | 0.0 (0.0; 4.4) | 0.0 (0.0; 1.8) | 22.2 (10.9; 33.5) | 11.1 (0.8; 21.4) | |
| 0.0 (0.0; 2.4) | 3.3 (0.8; 5.8) | 10.0 (3.8; 16.2) | 16.7 (9.6; 23.8) | 0.012 | |
| Serum tests | 0.0 (0.0; 6.4) | 3.2 (0.6; 5.8) | 9.7 (5.3; 14.1) | 6.5 (2.4; 10.6) | |
| Oral challenge | 0.0 (0.0; 0.0) | 14.3 (2.2; 28.8) | 42.9 (11.9;73.7) | 28.6 (6.9; 50.3) | |
| 4.4 (1.3; 7.5) | 6.7 (3.1; 10.3) | 24.4 (14.9; 33.8) | 22.2 (9.9; 34.6) | ||
| Steroids | 0.0 (0.0; 0.0) | 4.8 (0.4; 9.5) | 33.3 (11.3; 55.3) | 23.8 (3.9; 43.6) | |
| Desensitization | 0.0 (0.0; 0.0) | 0.0 (0.0; 2.4) | 33.3 (14.8; 51.9) | 41.7 (21.2; 62.2) | |
| ELD | 4.2 (1.5; 7.9) | 10.1 (2.2; 18.0) | 35.4 (21.7; 49.1) | 14.6 (4.5; 24.7) | |
| 7.7 (3.0; 12.4) | 3.8 (0.8; 7.0) | 11.5 (8.3; 15.0) | 19.2 (11.1; 27.4) | 0.221 | |
| 7.5 (0.5; 14.5) | 0.0 (0.0; 3.6) | 9.4 (4.3; 14.5) | 7.5 (2.1; 12.9) | ||
| Medically unconsulted | 9.4 (1.7; 17.1) | 13.2 (4.1; 22.3) | 32.1 (19.8; 44.4) | 26.4 (14.8; 38.0) | |
FA-–control group, FA+S–allergy to single food-origin allergen, FA+P–polyallergy to various food-origin allergens, FA+M–mixed polyallergy to aero- and food-origin allergens. ELD–elimination diet. Data are presented as percentages with 95% confidence intervals. Significant associations are marked in bold.
a p value of the Fisher’s exact test for comparison between groups with Bonferroni’s (PB) corrected significance threshold of 0.008.
b Classified according to the WHO classification [21, 22].
c Assessment or nutritional status [28].
Nutritional status of subjects and clinical parameters (allergic and inflammatory markers) in men and women by health status categories.
| Control Group (FA-) | Food allergy (FA+) | ||||||
|---|---|---|---|---|---|---|---|
| FA+S | FA+P | FA+M | |||||
| 0.21 (-0.57–0.88) | -0.37 (-1.65–1.34) | 0.286 | -0.43 (-2.50–1.38) | 0.071 | 0.49 (-1.36–1.79) | 0.805 | |
| | 0.12 (-0.78–0.99) | -0.78 (-2.19–2.18) | -0.33 (-2.50–1.43) | 0.222 | -0.55 (-2.61–3.06) | 0.189 | |
| | 0.07 (-1.01–1.30) | -0.66 (-1.12–0.18) | 0.278 | -0.68 (-2.39–1.02) | 0.149 | 0.11 (-2.84–1.82) | 0.912 |
| | 0.10 (-1.00–0.80) | -0.42 (-2.35–1.06) | -0.49 (-2.82–2.35) | -0.51 (-2.43–2.69) | |||
| Total-IgE | 26.31 [14.4] | 521.8 [398.3] | 0.281 | 223.9 [190.7] | 0.326 | 709.2 [535.3] | |
| Total-IgE | 33.1 [16.6] | 840.9 [578.8] | 1206.4 [486.8] | 922.2 [221.1] | |||
| Total- IgG | 3.84 [1.4] | 9.7 [6.3] | 0.067 | 9.5 [3.0] | 8.4 [4.6] | ||
| IL-2 | 9.91 [1.2] | 16.1 [2.2] | 0.613 | 25.1 [7.2] | 25.5 [11.7] | ||
| IL-4 | 9.77 [1.1]] | 49.5 [7.5] | 41.3 [9.6] | 40.5 [7.7] | |||
| INF-γ | 12.42 [2.5] | 15.4 [4.2] | 0.928 | 29.5 [9.9] | 26.5 [8.4] | ||
| 0.24 (-0.35–0.84) | -0.65 (-1.17–1.27) | 0.213 | -0.32 (-2.20–0.64) | -0.25 (-2.83–1.61) | |||
| | 0.16 (-0.95–1.52) | -0.76 (-1.76–1.15) | 0.064 | -0.41 (-2.60–1.00) | 0.320 | -0.13 (-1.87–2.51) | 0.454 |
| | 0.11 (-0.95–1.30) | 0.52 (-2.27–0.93) | 0.376 | -0.13 (-2.26–1.23) | 0.432 | -0.43 (-1.89–2.13) | |
| | 0.03 (-1.53–0.74) | 0.35 (-0.71–0.80) | 0.496 | -0.46 (-2.53–1.99) | -0.08 (-2.37–2.42) | 0.253 | |
| Total-IgE | 20.51 [10.8] | 116.5 [23.2] | 0.999 | 528.6 [182.3] | 0.296 | 893.4 [1189.4] | |
| Total-IgE | 31.21 [18.1] | 151.9 [13.2] | 0.999 | 400.4 [275.8] | 0.326 | 1332.7 [644.1] | |
| Total- IgG | 3.67 [1.4] | 5.5 [1.1] | 0.979 | 8.0 [2.6] | 10.1 [4.4] | ||
| IL-2 | 10.12 [1.4] | 10.4 [1.7] | 0.999 | 24.6 [7.6] | 25.1 [8.9] | ||
| IL-4 | 10.16 [1.1] | 42.9 [9.8] | 42.4 [9.6] | 41.8 [8.2] | |||
| INF-γ | 11.6 [2.6] | 10.9 [1.9] | 0.999 | 27.8 [10.8] | 28.3 [8.5] | ||
FA-–control group, FA+S–allergy to single food-origin allergen, FA+P–polyallergy to various food-origin allergens), FA+M–mixed polyallergy to aero- and food-origin allergens. Data are presented as the median (IQR) or means [SD]. Significant associations are marked in bold
a z-scores calculated for weight/height (W/H) and for weight/age (W/A) [21, 22]
b p value of the ANOVA-Tukey test for unequal sample sizes
c p value of the Friedman test for dependent groups in follow-up studies
d p-value of the t-test for the comparison male vs. female
Recruitment phase values
f Follow-up phase value
Odds ratios (OR) for ED prevalence in particular food allergy groups of males and females, compared to the correct weight category children adjusted for Adj.1: new-born feeding type, parent-reported food allergy, residence and Adj.2: Used allergy diagnostic method, dominant allergy symptoms, and therapy implementation.
| Prevalence of ED+ in particular food allergy (FA+) group | Male | Female | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OR Adj.1 | 95% CI | p (LR) | OR Adj.2 | 95% CI | p (LR) | OR Adj.1 | 95% CI | p (LR) | OR Adj.2 | 95% CI | p (LR) | ||
| FA+S | ≤ -2 | 0.81 | 0.40–1.62 | 0.551 | 0.90 | 0.31–2.62 | 0.847 | 1.99 | 0.88–4.52 | 0.101 | 1.91 | 1.05–3.45 | |
| ≥ +2 | 1.17 | 0.45–3.02 | 0.744 | 1.25 | 0.55–2.85 | 0.590 | 1.23 | 0.62–2.42 | 0.557 | 1.22 | 0.61–2.44 | 0.572 | |
| FA+P | ≤ -2 | 0.92 | 0.43–1.97 | 0.836 | 2.77 | 1.07–4.16 | 1.99 | 1.15–3.23 | 3.17 | 3.17–8.19 | |||
| ≥ +2 | 1.29 | 1.14–2.62 | 1.46 | 1.06–1.90 | 1.37 | 1.17–1.83 | 1.05 | 0.73–1.48 | 0.848 | ||||
| FA+M | ≤ -2 | 1.014 | 0.90–1.14 | 0.810 | 2.24 | 1.44–3.62 | 1.50 | 0.62–3.64 | 0.370 | 1.18 | 1.06–1.57 | ||
| ≥ +2 | 1.63 | 0.73–3.62 | 0.235 | 1.57 | 1.23–2.38 | 1.47 | 0.65–3.30 | 0.381 | 0.86 | 0.39–1.90 | 0.704 | ||
FA+S–allergy to single food-origin allergen, FA+P–polyallergy to various food-origin allergens), FA+M–mixed polyallergy to aero- and food-origin allergens. Significant associations are marked in bold.
a p (LR) value of the Wald likelihood ratio test (LR test) for significance evaluation of the model.